PDLIM5, PDZ and LIM domain 5, 10611

N. diseases: 148; N. variants: 19
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis
0.010 GeneticVariation disease BEFREE The four and a half LIM domain protein 2 (FHL2) is a member of the four and a half LIM domain (FHL) gene family, and it is associated with cholesterol-enriched diet-promoted atherosclerosis. 31714683 2020
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.010 GeneticVariation disease BEFREE The four and a half LIM domain protein 2 (FHL2) is a member of the four and a half LIM domain (FHL) gene family, and it is associated with cholesterol-enriched diet-promoted atherosclerosis. 31714683 2020
CUI: C0015967
Disease: Fever
Fever
0.010 Biomarker phenotype BEFREE Bacillus sp.TYF-LIM-B05, which is isolated from spoilage vinegar, is resistant to high temperature, high concentrated alcohol, acid, and salt, and can produce ethanol from mono-, di-, polysaccharide, and complex biomass as the sole carbon source. 31832840 2020
CUI: C0278878
Disease: Adult Glioblastoma
Adult Glioblastoma
0.010 Biomarker disease BEFREE Suppression of LIM Kinase 1 and LIM Kinase 2 Limits Glioblastoma Invasion. 31641031 2020
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma
0.010 Biomarker disease BEFREE Suppression of LIM Kinase 1 and LIM Kinase 2 Limits Glioblastoma Invasion. 31641031 2020
Malignant neoplasm of urinary bladder
0.010 GeneticVariation disease BEFREE As the mechanisms of LIMK-associated tumorigenesis are still unclear, we analyzed the tumorigenic functions of LIM kinase 2 (LIMK2) in human bladder cancer (BC) and explored whether the newly identified LIMK2 3´-UTR SNP rs2073859 (G-to-A allele) is correlated with clinical features. 30006972 2019
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm
0.010 GeneticVariation disease BEFREE As the mechanisms of LIMK-associated tumorigenesis are still unclear, we analyzed the tumorigenic functions of LIM kinase 2 (LIMK2) in human bladder cancer (BC) and explored whether the newly identified LIMK2 3´-UTR SNP rs2073859 (G-to-A allele) is correlated with clinical features. 30006972 2019
CUI: C0014175
Disease: Endometriosis
Endometriosis
0.010 AlteredExpression disease BEFREE The abnormally high expression of cytoskeletal regulators (LIM kinase 1 [LIMK1] and cofilin1) is closely related to increased invasiveness and proliferation of eutopic endometrial stromal cells from endometriosis patients compared to normal eutopic endometrial cells. 30808273 2019
CUI: C0018824
Disease: Heart valve disease
Heart valve disease
0.010 Biomarker group BEFREE LIM kinase 1 acts as a profibrotic mediator in permanent atrial fibrillation patients with valvular heart disease. 30837367 2019
CUI: C0677886
Disease: Epithelial ovarian cancer
Epithelial ovarian cancer
0.010 AlteredExpression disease BEFREE We also analyzed the mRNA levels of target genes that candidate miRNAs might regulate in patient tissues. miR-214-3p was highly expressed in tissues and exosomes derived from EOC with high malignancy and also found to regulate the expression of LIM homeobox domain 6 (LHX6) mRNA. 31810245 2019
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.010 GeneticVariation disease BEFREE As the mechanisms of LIMK-associated tumorigenesis are still unclear, we analyzed the tumorigenic functions of LIM kinase 2 (LIMK2) in human bladder cancer (BC) and explored whether the newly identified LIMK2 3´-UTR SNP rs2073859 (G-to-A allele) is correlated with clinical features. 30006972 2019
CUI: C1299433
Disease: Left main coronary artery disease
Left main coronary artery disease
0.010 Biomarker disease BEFREE To demonstrate the noninferiority of the BiOSS LIM C sirolimus-eluting cobalt-chromium bifurcation dedicated stent against the Xience stent regarding patients oriented composite endpoint (POCE) at 12 months among patients with left main coronary artery disease (LMCA). 31543500 2019
CUI: C1449563
Disease: Cardiomyopathy, Familial Idiopathic
Cardiomyopathy, Familial Idiopathic
0.010 Biomarker disease BEFREE Since PDLIM3 and PDLIM5 are candidate IDCM susceptibility genes, the current study aims to investigate whether polymorphisms within PDLIM3 and PDLIM5 could be correlated with IDCM. 31424159 2019
CUI: C0024301
Disease: Lymphoma, Follicular
Lymphoma, Follicular
0.010 AlteredExpression disease BEFREE We evaluated MEF2B expression, in comparison with additional GC markers, LIM domain-only transcription factor 2 (LMO2), and human GC-associated lymphoma (HGAL), in a variety of B-cell lymphomas, with particular emphasis on their utility in differentiating FL from MZL. 29309299 2018
CUI: C0038454
Disease: Cerebrovascular accident
Cerebrovascular accident
0.010 Biomarker group BEFREE Rac1 inhibition led to inactivation of pro-regenerative molecules, including mitogen-activated protein kinase kinase (p-MEK)1/2, LIM domain kinase (LIMK)1, and extracellular signal-regulated kinase (p-ERK)1/2 at 14 days after stroke. 29476448 2018
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.010 Biomarker group BEFREE We evaluated MEF2B expression, in comparison with additional GC markers, LIM domain-only transcription factor 2 (LMO2), and human GC-associated lymphoma (HGAL), in a variety of B-cell lymphomas, with particular emphasis on their utility in differentiating FL from MZL. 29309299 2018
CUI: C0238463
Disease: Papillary thyroid carcinoma
Papillary thyroid carcinoma
0.010 AlteredExpression disease BEFREE Thus, we suggested that PDLIM5 promotes PTC via activation of the Ras-ERK pathway. 29574154 2018
CUI: C0940937
Disease: precancerous lesions
precancerous lesions
0.010 Biomarker phenotype BEFREE We identified that LIM domain kinase (LIMK)2 was progressively downregulated with tumor progression from precancerous lesions to advanced cancer. 29970879 2018
CUI: C1367654
Disease: Marginal Zone B-Cell Lymphoma
Marginal Zone B-Cell Lymphoma
0.010 AlteredExpression disease BEFREE We evaluated MEF2B expression, in comparison with additional GC markers, LIM domain-only transcription factor 2 (LMO2), and human GC-associated lymphoma (HGAL), in a variety of B-cell lymphomas, with particular emphasis on their utility in differentiating FL from MZL. 29309299 2018
CUI: C1384666
Disease: hearing impairment
hearing impairment
0.010 Biomarker phenotype BEFREE Age-matched groups of older adults with either age-appropriate hearing (ENH, <i>n</i> = 20) or aided hearing impairment (EHI, <i>n</i> = 21) participated. 29867654 2018
Non ST segment elevation acute coronary syndrome
0.010 Biomarker disease BEFREE In POLBOS trials dedicated bifurcation BiOSS® stents were compared with regular drug eluting stents (rDES) in patients with stable coronary artery disease or non ST-segment elevation acute coronary syndrome (POLBOS I: paclitaxel eluting BiOSS® Expert vs. rDES; POLBOS II: sirolimus eluting BiOSS® LIM vs. rDES). 28840591 2018
CUI: C0001973
Disease: Alcoholic Intoxication, Chronic
Alcoholic Intoxication, Chronic
0.010 GeneticVariation disease BEFREE Polymorphisms in PDLIM5 gene are associated with alcohol dependence, type 2 diabetes, and hypertension. 27693979 2017
CUI: C0003872
Disease: Arthritis, Psoriatic
Arthritis, Psoriatic
0.010 Biomarker disease BEFREE The LIM-Only Protein Four and a Half LIM Domain Protein 2 Attenuates Development of Psoriatic Arthritis by Blocking Adam17-Mediated Tumor Necrosis Factor Release. 28823868 2017
CUI: C0016667
Disease: Fragile X Syndrome
Fragile X Syndrome
0.010 Biomarker disease BEFREE We previously found that the activation of LIM kinase 1 (LIMK1) downstream of augmented synthesis of bone morphogenetic protein (BMP) type 2 receptor (BMPR2) promotes aberrant synaptic development in mouse and <i>Drosophila</i> models of FXS and that these molecular and cellular markers were correlated in patients with FXS. 28465421 2017
CUI: C0027796
Disease: Neuralgia
Neuralgia
0.010 Biomarker phenotype BEFREE These results suggest the possible applicability of LIM, uncomplexed or complexed with βCD, in conditions such as FM and neuropathic pain, for which there are currently only limited pharmacological options. 28673718 2017